Diabetes therapies in renal impairment

British Journal of Diabetes and Vascular Disease

Volumn 12, Issue 4, 2012, Pages 167-171

  Bailey, Clifford J ^a   Day, Caroline ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Albuminuria; drug therapy; kidney disease; renal impairment; type 2 diabetes

Indexed keywords

ACARBOSE; ALBUMIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; VILDAGLIPTIN;

CHRONIC KIDNEY FAILURE; COMORBIDITY; DIALYSIS; DISEASE SEVERITY; DRUG METABOLISM; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

EID: 84866512217     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.1177/1474651412458811     Document Type: Review

References (46)

1. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984 ; 26: 861-8
2. Kasiske BL. Relationship between vascular disease and age-associated changes in the human kidney. Kidney Int. 1987 ; 31: 1153-9
3. Praga M. Obesity: a neglected culprit in renal disease. Nephrol Dial Transplant. 2002 ; 17: 1157-9
4. Pavkov ME, Knowler WC, Lemley KV, et al. Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol. 2012 ; 7: 78-84
5. Standards of Medical Care in Diabetes: 2012. Diabetes Care. 2012 ; 35 (suppl 1). S11 - S63
6. Marshall SM, Flyvbjerg A Textbook of Diabetes. 4 th edn.Chichester: Wiley-Blackwell, 2010:599-614. Holt R Cockram C Flyvbjerg A Goldstein B, ed. Chichester: Wiley-Blackwell ; 599-614.
7. Girman CJ, Kou TD, Brodovicz K, et al. Risk of acute renal failure in patients with type 2 diabetes mellitus. Diabet Med. 2012 ; 29: 614-21
8. KDOQI. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. www.kidney.org/professionals/ kdoqi/guidelines-ckd/toc.htm. Accessed June 2012.
9. MacGregor MS, Boag DE, Innes A. Chronic kidney disease: evolving strategies for detection and management of impaired renal function. Q J Med. 2006 ; 99: 365-75
10. Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. JASN. 2008 ; 19: 844-46
11. Rognant N, Lemoine S, Laville M, et al. Performance of the chronic kidney disease epidemiology collaboration equation to estimate glomerular filtration rate in diabetic patients. Diabetes Care. 2011 ; 34: 1320-2
12. Lemley KV, Abdullah I, Myers BD, et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int. 2000 ; 58: 1228-37
13. Myers BD, Nelson RG, Tan M, et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int. 1995 ; 47: 1781-9
14. Wright J, Vardhan A. The problem of diabetic nephropathy and practical prevention of its progression. Br J Diabetes Vasc Dis. 2008 ; 8: 272-7
15. Ritz E, Rychlík I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999 ; 34: 795-808
16. Atlas of End-Stage Renal Disease in the United States2007. ESRD Incidence and Prevalence. www.usrds.org/2007/view/02-incid-prev.asp
17. Abaterusso C, Lupo A, Ortalda V, et al. Treating elderly people with diabetes and stages 3 and chronic kidney disease. Clin J Am Soc Nephrol. 2008 ; 3: 1185-94
18. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005 ; 16: 489-95
19. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med. 2004 ; 351: 1296-305
20. Sarnak MJ. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils. Circulation. 2003 ; 108: 2154-69
21. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population level cohort study. Lancet. 2012 ;:
22. Basi S, Fesler P, Mimran A, Lewis JB. Microalbuminuria in type 2 diabetes and hypertension A marker, treatment target, or innocent bystander?. Diabetes Care. 2008 ; 31 (suppl 2). S194-201
23. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-59
24. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med. 2008 ; 358: 2560-72
25. Duckworth W, Abraira C, Mortitz T, et al. Glucose control and vcascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 ; 360: 129-39
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 ; 359: 1577-89
27. Metformin. Summary of product characteristics. Revised 12October2010. www.medicines.org.uk/emc/medicine/1043/SPC/glucophage
28. NICE clinical guideline 87. The management of type 2 diabetes. Revised May2009. www.nice.org.uk/nicemedia/pdf/CG87QuickRefGuide.pdf
29. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011 ; 34: 1431-7
30. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004 ; 64: 1339-58
31. Glibenclamide. Summary of product characteristics. www.drugs.com/uk/ glibenclamide-2-5mg-tablets-spc-9871.html
32. Glimepiride. Summary of product characteristics. www.medicines.org.uk/ emc/medicine/26198
33. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes. Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005 ; 28: 2948-61
34. British National Formulary. www.bnf.org/bnf/login.htm?uri=bnf/current/
35. Repaglinide. Summary of product characteristics. www.medicines.org.uk/ EMC/medicine/18980/SPC/Prandin+0.5mg,+1mg,+2mg+Tablets/
36. Nateglinide. Summary of product characteristics. www.medicines.org.uk/ emc/medicine/4622/SPC/
37. Pioglitazone. Summary of product characteristics. www.medicines.org.uk/ emc/medicine/4236
38. Acarbose. Summary of product characteristics. www.medicines.org.uk/emc/ medicine/19972/SPC/Glucobay+50mg+tablets/
39. Exenatide. Summary of product characteristics. www.medicines.org.uk/emc/ medicine/19257
40. Liraglutide. Summary of product characteristics. www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/001026/WC500050017.pdf
41. Sitagliptin. Summary of product characteristics. Revised 12March2012. www.medicines.org.uk/emc/medicine/19609
42. Vildagliptin. Summary of product characteristics. Revised 2February2012. www.medicines.org.uk/emc/medicine/20734
43. Saxagliptin. Summary of product characteristics. Revised 11January2012. www.medicines.org.uk/emc/medicine/22315
44. Linagliptin. Summary of product characteristicswww.medicines.org.uk/EMC/ medicine/25000
45. Sloan L, Newman J, Sauce C, et al. Safety and efficacy of linagiptin in type 2 diabetes patients with severe renal impairment. Diabetes. 2011 ; 60 ( suppl 1 ):
46. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998 ; 19: 608-24